# US 2021/0087215 A1 · Lincosamide antibiotics and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0087215 A1
- Document ID: US20210087215A1
- Status: Published application
- Kind: A1
- Application number: 16/637,477
- Filed: 2018-08-10
- Published: 2021-03-25
- Earliest claimed: 2017-08-10
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Andrew G. Myers; Matthew James Mitcheltree
- Web page: https://patentgrep.com/patent/US20210087215A1

## CPC

- A61P 31/04: Antibacterial agents
- C07H 15/16: Lincomycin; Derivatives thereof
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the C-7 position of the aminooctose (northern) region, thus distinguishing them from lincomycin and clindamycin. Also provided are methods for preparing the lincosamide compounds, pharmaceutical compositions comprising the lincosamide compounds, and methods of treating infectious diseases using the disclosed lincosamide compounds.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
P is independently hydrogen or a protecting group;
A is substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,
or A and R7 are joined to forma substituted or unsubstituted heterocyclic ring;
R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaralkyl, substituted or unsubstituted heteroaliphatic, —ORA, —N(RA)2, or —SRA;
R2 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaliphatic, —ORA, —N3, —N(RA)2, —SRA, —CN, —SCN, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)N(RA)2, —C(═O)RA, —C(═O)ORA, —C(═O)N(RA)2, —NO2, —NRAC(═O)RA, —NRAC(═O)ORA, —NRAC(═O)N(RA)2, —NRAC(═NRA)N(RA)2, —OC(═O)RA, —OC(═O)ORA, —OC(═O)N(RA)2, —NRAS(O)2RA, —OS(O)2RA, or —S(O)2RA;
R3 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroaliphatic;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroaliphatic;
R5 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroaliphatic;
R6a, R6b, and R6c are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaliphatic, or substituted or unsubstituted acyl;
R7 is hydrogen or unsubstituted alkyl; or A and R7 are joined to form a substituted or unsubstituted heterocyclic ring;
R8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaliphatic, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)N(RA)2, —C(═O)RA, —C(═O)ORA, —C(═O)N(RA)2, —S(O)2RA, or a nitrogen protecting group;
each occurrence of R9 is independently, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaliphatic, —ORA, —N(RA)2, —SRA, —CN, —SCN, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)N(RA)2, —C(═O)RA, —C(═O)ORA, —C(═O)N(RA)2, —NO2, —NRAC(═O)RA, —NRAC(═O)ORA, —NRAC(═O)N(RA)2, —NRAC(═NRA)N(RA)2, —OC(═O)RA, —OC(═O)ORA, —OC(═O)N(RA)2, —NRAS(O)2RA, —OS(O)2RA, or —S(O)2RA;
n is 1 or 2;
p is 1-3;
each occurrence of RA is, independently, hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted carbocyclyl, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted hetaralkyl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two RA groups are joined to form a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heteroaryl ring;
provided that when R1 is —SRA and RA is C1-6 substituted or unsubstituted alkyl, A is not unsubstituted C3-6 cycloalkyl,
wherein RA is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted acyl; and
provided that when A is
R1 is not —ORA, wherein RA is substituted or unsubstituted alkyl or substituted or unsubstituted alkyl.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
A is

### Claim 6 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein:
R2 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkyl, —ORA, —N3, —N(RA)2, —SRA, —NRAC(═O)RA, or —OC(═O)N(RA)2.

### Claim at position 5

7-9. (canceled)

### Claim 10 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein:
R3 is hydrogen, halogen, substituted or unsubstituted alkyl, or substituted or unsubstituted alkenyl.

### Claim at position 7

11-12. (canceled)

### Claim 13 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein:
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, or substituted or unsubstituted alkenyl.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 16 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
A is

### Claim at position 12

17-18. (canceled)

### Claim 19 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
A is

### Claim at position 14

20-21. (canceled)

### Claim 22 (depends on 1)

The compound of any claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaralkyl, substituted or unsubstituted heteroalkyl, —ORA, —N(RA)2, or —SRA.

### Claim at position 16

23-24. (canceled)

### Claim 25 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is
wherein R1a and R1b are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaliphatic, —ORA, —N3, —N(RA)2, —SRA, —CN, —SCN, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)N(RA)2, —C(═O)RA, —C(═O)ORA, —C(═O)N(RA)2, —NO2, —NRAC(═O)RA, —NRAC(═O)ORA, —NRAC(═O)N(RA)2, —NRAC(═NRA)N(RA)2, —OC(═O)RA, —OC(═O)ORA, —OC(═O)N(RA)2, —NRAS(O)2RA, —OS(O)2RA, or —S(O)2RA, or R1a and R1b are joined to form a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted carbocyclic ring.

### Claim at position 18

26-27. (canceled)

### Claim 28 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is

### Claim at position 20

29-32. (canceled)

### Claim 33 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R8 is hydrogen, substituted or unsubstituted alkyl, or —C(═O)RA.

### Claim at position 22

34-36. (canceled)

### Claim 37 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heteroalkyl.

### Claim at position 24

38-42. (canceled)

### Claim 43 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (I-a), (I-b), (I-c), or (I-d):
or a pharmaceutically acceptable salt thereof.

### Claim at position 26

44-46. (canceled)

### Claim 47 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (II), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), or (II-g):
or a pharmaceutically acceptable salt thereof, wherein:
R1a and R1b are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaliphatic, —ORA, —N3, —N(RA)2, —SRA, —CN, —SCN, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)N(RA)2, —C(═O)RA, —C(═O)ORA, —C(═O)N(RA)2, —NO2, —NRAC(═O)RA, —NRAC(═O)ORA, —NRAC(═O)N(RA)2, —NRAC(═NRA)N(RA)2, —OC(═O)RA, —OC(═O)ORA, —OC(═O)N(RA)2, —NRAS(O)2RA, —OS(O)2RA, or —S(O)2RA, or R1a and R1b are joined to form a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted carbocyclic ring.

### Claim at position 28

48-54. (canceled)

### Claim 55 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (III), (III-a), (IV), or (IV-a):
or a pharmaceutically acceptable salt thereof.

### Claim at position 30

56-58. (canceled)

### Claim 59 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is:

### Claim 60

(canceled)

### Claim 61 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 62

(canceled)

### Claim 63 (depends on 1)

A method of treating an infectious disease comprising administering an effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

### Claim at position 36

64-69. (canceled)

### Claim 70 (depends on 1)

A method of killing or inhibiting the growth of a microorganism comprising contacting the microorganism with an effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

### Claim at position 38

71-74. (canceled)
